BioRem (BRM) Q3 2026 earnings summary

Executive summary

• Record Q3 revenue of $16.6M, up 48% YoY; net earnings reached $2.7M, or $0.158 basic EPS.

• Nine-month revenue and earnings also set records at $39.1M and $6.6M, respectively.

Financial highlights

• Q3 revenue was $16.631M versus $11.253M in Q3 2025 and $15.689M in Q2 2026.

• Gross profit was $5.644M versus $3.166M YoY; operating expenses were $1.965M versus $1.552M.

• Net earnings were $2.691M versus $1.158M YoY; basic EPS was $0.158 versus $0.072 and diluted EPS was $0.148 versus $0.062.

Outlook and guidance

• Management cited a strong project pipeline and future potential from new products and services offered to its customer base.

• Many projects were ahead of schedule, while management said project execution remained strong.